Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 195.05 INR
Change Today 0.00 / 0.00%
Volume 0.0
BLIS On Other Exchanges
Symbol
Exchange
BLIS is not on other exchanges.
As of 7:06 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

bliss gvs pharma ltd (BLIS) Snapshot

Open
197.00
Previous Close
196.65
Day High
200.30
Day Low
194.00
52 Week High
07/29/15 - 204.00
52 Week Low
08/21/14 - 43.40
Market Cap
20.1B
Average Volume 10 Days
949.2K
EPS TTM
5.81
Shares Outstanding
103.1M
EX-Date
09/8/15
P/E TM
33.6x
Dividend
0.50
Dividend Yield
0.36%
Current Stock Chart for BLISS GVS PHARMA LTD (BLIS)

Related News

No related news articles were found.

bliss gvs pharma ltd (BLIS) Related Businessweek News

No Related Businessweek News Found

bliss gvs pharma ltd (BLIS) Details

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers therapeutic products, such as anti-fungal, laxative, anti-haemorrhoidal, anti-spasmodic, anti-malarial, anti-biotic, anti-microbial, anthelmintic, anti-diarrhoeal, anti-inflammatory, anti-pyretic, analgesic, anti-diabetic, anti-hypertensive, anti-emetic, anti-depressant, erectile dysfunction, multivitamin, anti-allergic, and antacid. It also provides over-the counter products, including herbal lozenges, shampoos, medicated dusting powders, herbal roll on products, and medicated and moisturizing soaps. In addition, the company provides female contraceptive under the Today brand name; and contract manufacturing services, as well as trades in pharmaceuticals. The company offers its products in various dosage forms, such as suppositories; pessaries; tablets; capsules; suspensions; syrups; dry powder injectables; injectables in ampoules; eye/ear/nasal drops; soft gelatin capsules; creams, gels, and ointments; and transdermal patches. The company was incorporated in 1984 and is based in Mumbai, India.

Founded in 1984

bliss gvs pharma ltd (BLIS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

bliss gvs pharma ltd (BLIS) Key Developments

Bliss GVS Pharma Ltd Declares Final Dividend; Announces Resignation of G.G Desai from the Board

Bliss GVS Pharma Ltd. announced that the board of directors of the company at its meeting held on May 29, 2015, has considered and approved final dividend at the rate of 50% that is INR 0.50 per share. The company also announced that due to ill health Mr. G.G Desai resigned from the Board.

Bliss Gvs Pharma Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015

Bliss Gvs Pharma Limited reported unaudited standalone and consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, on standalone basis, Net Sales were INR 679.632 million compared to INR 537.314 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 115.087 million compared to INR 58.721 million a year ago. Profit from ordinary activities before tax was INR 106.761 million against INR 42.345 million a year ago. Net profit was INR 64.610 million or INR 0.63 per basic and diluted share compared to net profit of INR 15.145 million or INR 0.15 per basic and diluted share a year ago. For the full year, on standalone basis, net sales were INR 3,094.589 million compared to INR 2,834.925 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 811.159 million compared to INR 616.105 million a year ago. Profit from ordinary activities before tax was INR 912.545 million against INR 822.984 million a year ago. Net profit was INR 600.155 million or INR 5.82 per basic and diluted share compared to net profit of INR 539.265 million or INR 5.23 per basic and diluted share a year ago. For the year, on consolidated basis, net sales were INR 4,030.734 million compared to INR 3,397.326 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 921.430 million compared to INR 605.386 million a year ago. Profit from ordinary activities before tax was INR 960.192 million against INR 705.582 million a year ago. Net profit was INR 613.934 million or INR 5.81 per basic and diluted share compared to net profit of INR 410.315 million or INR 3.97 per basic and diluted share a year ago.

Bliss Gvs Pharma Limited to Report Fiscal Year 2015 Results on May 29, 2015

Bliss Gvs Pharma Limited announced that they will report fiscal year 2015 results on May 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLIS:IN 195.05 INR 0.00

BLIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLIS.
View Industry Companies
 

Industry Analysis

BLIS

Industry Average

Valuation BLIS Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLISS GVS PHARMA LTD, please visit www.blissgvspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.